CagriSema

Adult Dosing .

Dosage forms:  INJ (pen)

Investigational New Drug (IND)

[pending FDA approval]

weight management, chronic

[indication/patient population pending FDA approval]

Info: cagrilintide binds amylin receptors, decreasing glucagon secretion, delaying gastric emptying, and modulating satiety; semaglutide activates glucagon-like-peptide-1 (GLP-1) receptor, regulating appetite and caloric restriction, increasing insulin secretion, decreasing glucagon secretion, and delaying gastric emptying (incretin mimetic)

Peds Dosing .

Dosage forms:  --

Investigational New Drug (IND)

[pending FDA approval]

Info: not anticipated to be applicable to Peds population